Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.53 |
| ▸ | BCHE | P06276 | 3/20 | 0.53 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | NPR1 | P16066 | 3/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | USP1 | O94782 | 1/20 | 0.41 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | TOP1 | P11387 | 1/20 | 0.40 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21542062 | 0.86 | CDK2 (0.51) | APPBCHEACHENPR1PIP4K2C | |
| SCHEMBL21567224 | 0.83 | APP (0.77) | APPBCHEACHECTNNB1TCF7L2 | |
| SCHEMBL30092996 | 0.83 | APP (0.77) | APPBCHEACHECTNNB1TCF7L2 | |
| SCHEMBL20400138 | 0.83 | BCHE (0.45) | APPBCHEACHECDK1NPR1 | |
| SCHEMBL21542070 | 0.83 | APP (0.53) | APPBCHEACHECDK1NPR1 | |
| SCHEMBL30092878 | 0.83 | BCHE (0.53) | APPBCHEACHENPR1CTNNB1 | |
| SCHEMBL21567262 | 0.83 | BCHE (0.53) | APPBCHEACHENPR1CTNNB1 | |
| SCHEMBL21542032 | 0.82 | BCHE (0.52) | APPBCHEACHENPR1EGFR | |
| SCHEMBL21567419 | 0.82 | CDK1 (0.48) | APPBCHEACHECDK1NPR1 | |
| SCHEMBL21542001 | 0.77 | PDE4A (0.49) | APPBCHEACHENPR1USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2026-02-10 | — | — | US | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20190345157-A1 | COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
| US-20190345157-A1 | COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | CBR1, CBR3, COX6C | APP 4837/4885BCHE 2784/4885ACHE 2483/4885 |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | PWWP2B, WARS1, PNPO | APP 3897/4885BCHE 3860/4885ACHE 1710/4885 |
| US-20190345157-A1 | COMPOUNDS | ABCB11, LTC4S, AQP1 | APP 2829/4885BCHE 632/4885ACHE 297/4885 |
| US-11518760-B2 | Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds | P2RX5, PNPO, P2RX3 | APP 4242/4885BCHE 3579/4885ACHE 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.